The number of people needing dialysis is also rising fast, from 2.8 lakh patients in 2024 to 5.2 lakh patients by 2029, and it is a strong 12.7% CAGR. Nephrocare Limited has been working in this competitive space and will make its debut in the Indian stock market.
ICICI Securities, Ambit Private, IIFL Capital Services, and Nomura Financial Advisory will manage the issue, while Kfin Technologies will register it. Don't forget to view the Nephrocare IPO allotment status.
Analyse the IPO through Nephrocare DRHP and RHP.
Note: 50% of shares will be unlocked 30 days after allotment, while the rest will be free from lock-in restrictions after 90 days.
Get a better Nephrocare IPO review through the details mentioned below:
The important risks and strengths of Nephrocare Limited are mentioned below:
Strengths
Strong Presence in Dialysis Services: Nephrocare has built a trusted name in dialysis care with a growing network of clinics across India.
Experienced Medical Team: The company benefits from highly skilled nephrologists, trained technicians, and experienced nursing staff. Their expertise ensures safe and consistent patient care, which strengthens trust and long-term patient relationships.
Diverse Operating Models: Nephrocare operates through multiple formats like standalone clinics, hospital-based units, and PPP (public-private partnership) centres.
Focus on Quality and Technology: With modern dialysis machines, strict clinical protocols, and digital monitoring systems, Nephrocare emphasises precision and safety.
Risks
Quality and Compliance Risks: If dialysis services do not meet strict medical standards, it can lead to legal issues, patient complaints, and damage to the company’s reputation and performance.
Dependence on Skilled Healthcare Staff: The business relies heavily on qualified doctors, technicians, and nurses. Difficulty in attracting or retaining them can directly affect service quality and operations.
Challenges in Expanding to New Locations: Expanding into new cities or countries may involve regulatory, operational, or infrastructure hurdles.
Operational Disruptions and PPP-Related Risks: Interruptions at standalone, captive, or PPP clinics or failure to meet PPP contract terms could lead to losses, blacklisting, and reduced future opportunities.
As of December 3, 2025, the Nephroplus IPO GMP has not been updated. You can view the IPO's live GMP and the subscription status. Also, check the Nephrocare Limited DRHP and RHP before you click on the Apply Now button.
1. How is the Nephrocare IPO review?
Nephrocare has a clinic chain across India. The total IPO size is unavailable, and the listing date is 17 December 2025. For the latest details, you can also look for the GMP updates.
2. What is the Nephrocare IPO date?
The IPO opening is 10 December 2025, and the closing date is 12 December 2025. Live subscription details can be monitored through FinnPick.
3. What is the Nephrocare IPO price today?
The Nephrocare IPO price is unavailable as of December 3, 2025. Also, don't forget to check the Nephrocare IPO DRHP and RHP.
4. Do I need a demat account to bid for the Nephrocare Limited IPO?
Yes, a demat account is required to bid for the Nephrocare Limited IPO. Click here to get the ultimate list of the top demat account providers.
